News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
605,330 Results
Type
Article (43423)
Company Profile (320)
Press Release (561586)
Multimedia
Podcasts (81)
Webinars (13)
Section
Business (168120)
Career Advice (2450)
Deals (30406)
Drug Delivery (108)
Drug Development (78919)
Employer Resources (148)
FDA (14514)
Job Trends (13034)
News (296851)
Policy (28634)
Tag
Academia (2682)
Academic (1)
Accelerated approval (10)
Adcomms (29)
Allergies (98)
Alliances (43134)
ALS (117)
Alzheimer's disease (1515)
Antibody-drug conjugate (ADC) (175)
Approvals (14494)
Artificial intelligence (315)
Autoimmune disease (34)
Automation (18)
Bankruptcy (327)
Best Places to Work (10684)
BIOSECURE Act (16)
Biosimilars (112)
Biotechnology (259)
Bladder cancer (97)
Brain cancer (37)
Breast cancer (373)
Cancer (2928)
Cardiovascular disease (232)
Career advice (2063)
Career pathing (32)
CAR-T (195)
CDC (28)
Cell therapy (524)
Cervical cancer (21)
Clinical research (64832)
Collaboration (1021)
Company closure (3)
Compensation (504)
Complete response letters (29)
COVID-19 (2604)
CRISPR (67)
C-suite (353)
Cystic fibrosis (115)
Data (3025)
Decentralized trials (2)
Denatured (16)
Depression (74)
Diabetes (346)
Diagnostics (5893)
Digital health (19)
Diversity (5)
Diversity, equity & inclusion (41)
Drug discovery (143)
Drug pricing (124)
Drug shortages (25)
Duchenne muscular dystrophy (135)
Earnings (62680)
Editorial (43)
Employer branding (20)
Employer resources (137)
Events (91386)
Executive appointments (881)
FDA (16122)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (917)
Gene editing (142)
Generative AI (24)
Gene therapy (412)
GLP-1 (819)
Government (4344)
Grass and pollen (5)
Guidances (178)
Healthcare (17293)
HIV (41)
Huntington's disease (32)
IgA nephropathy (44)
Immunology and inflammation (173)
Immuno-oncology (9)
Indications (39)
Infectious disease (2782)
Inflammatory bowel disease (160)
Inflation Reduction Act (13)
Influenza (66)
Intellectual property (122)
Interviews (524)
IPO (14344)
IRA (49)
Job creations (2762)
Job search strategy (1685)
Kidney cancer (15)
Labor market (34)
Layoffs (492)
Leadership (26)
Legal (6093)
Liver cancer (80)
Longevity (10)
Lung cancer (420)
Lymphoma (205)
Machine learning (11)
Management (52)
Manufacturing (366)
MASH (99)
Medical device (11215)
Medtech (11219)
Mergers & acquisitions (16750)
Metabolic disorders (874)
Multiple sclerosis (97)
NASH (23)
Neurodegenerative disease (131)
Neuropsychiatric disorders (42)
Neuroscience (2236)
NextGen: Class of 2025 (5974)
Non-profit (4129)
Now hiring (43)
Obesity (435)
Opinion (250)
Ovarian cancer (101)
Pain (111)
Pancreatic cancer (120)
Parkinson's disease (193)
Partnered (21)
Patents (300)
Patient recruitment (165)
Peanut (52)
People (54709)
Pharmaceutical (55)
Pharmacy benefit managers (16)
Phase I (20363)
Phase II (28637)
Phase III (21307)
Pipeline (1644)
Policy (203)
Postmarket research (2391)
Preclinical (8642)
Press Release (60)
Prostate cancer (142)
Psychedelics (45)
Radiopharmaceuticals (266)
Rare diseases (502)
Real estate (4512)
Recruiting (61)
Regulatory (20708)
Reports (29)
Research institute (2286)
Resumes & cover letters (360)
Rett syndrome (10)
RNA editing (10)
RSV (46)
Schizophrenia (95)
Series A (158)
Series B (110)
Service/supplier (3)
Sickle cell disease (64)
Special edition (16)
Spinal muscular atrophy (154)
Sponsored (31)
Startups (3198)
State (2)
Stomach cancer (15)
Supply chain (67)
Tariffs (49)
The Weekly (64)
Vaccines (762)
Venture capital (54)
Weight loss (277)
Women's health (38)
Worklife (17)
Date
Today (75)
Last 7 days (329)
Last 30 days (1729)
Last 365 days (29863)
2025 (16236)
2024 (33634)
2023 (37498)
2022 (48412)
2021 (52024)
2020 (50008)
2019 (42544)
2018 (32072)
2017 (29660)
2016 (28193)
2015 (32972)
2014 (25387)
2013 (20574)
2012 (21784)
2011 (22690)
2010 (20430)
Location
Africa (744)
Alabama (65)
Alaska (4)
Arizona (180)
Arkansas (12)
Asia (36816)
Australia (7278)
California (6964)
Canada (2282)
China (665)
Colorado (300)
Connecticut (281)
Delaware (190)
Europe (82661)
Florida (1048)
Georgia (226)
Hawaii (1)
Idaho (57)
Illinois (590)
India (26)
Indiana (318)
Iowa (15)
Japan (227)
Kansas (99)
Kentucky (26)
Louisiana (14)
Maine (53)
Maryland (973)
Massachusetts (5180)
Michigan (229)
Minnesota (399)
Mississippi (3)
Missouri (87)
Montana (24)
Nebraska (22)
Nevada (74)
New Hampshire (68)
New Jersey (1998)
New Mexico (25)
New York (1958)
North Carolina (1031)
North Dakota (7)
Northern California (3015)
Ohio (209)
Oklahoma (12)
Oregon (33)
Pennsylvania (1470)
Puerto Rico (17)
Rhode Island (33)
South America (1017)
South Carolina (31)
South Dakota (1)
Southern California (2673)
Tennessee (111)
Texas (1045)
United States (25728)
Utah (213)
Virginia (171)
Washington D.C. (65)
Washington State (601)
West Virginia (4)
Wisconsin (62)
605,330 Results for "aquestive therapeutics formerly known as monosolrx".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
July 8, 2025
·
2 min read
Press Releases
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film
July 16, 2025
·
9 min read
Press Releases
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference
May 5, 2025
·
3 min read
Press Releases
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
·
32 min read
Press Releases
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions
June 16, 2025
·
9 min read
Press Releases
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
April 9, 2025
·
2 min read
Press Releases
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit
June 25, 2025
·
8 min read
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Press Releases
Aquestive Therapeutics to Participate in Two Upcoming Conferences in March
February 26, 2025
·
3 min read
Pharm Country
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Aquestive Therapeutics, Inc. announced that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host investor meetings on July 9, 2024.
June 27, 2024
·
2 min read
1 of 60,533
Next
